312 related articles for article (PubMed ID: 30186457)
1. Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugs.
Jiang N; Lin JJ; Wang J; Zhang BN; Li A; Chen ZY; Guo S; Li BB; Duan YZ; Yan RY; Yan HF; Fu XY; Zhou JL; Yang HM; Cui Y
Exp Ther Med; 2018 Sep; 16(3):2183-2192. PubMed ID: 30186457
[TBL] [Abstract][Full Text] [Related]
2. Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer.
Ferrando-Díez A; Felip E; Pous A; Bergamino Sirven M; Margelí M
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884366
[TBL] [Abstract][Full Text] [Related]
3. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.
von Arx C; De Placido P; Caltavituro A; Di Rienzo R; Buonaiuto R; De Laurentiis M; Arpino G; Puglisi F; Giuliano M; Del Mastro L
Cancer Treat Rev; 2023 Feb; 113():102500. PubMed ID: 36587473
[TBL] [Abstract][Full Text] [Related]
4. Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer.
Singh DD; Lee HJ; Yadav DK
Front Pharmacol; 2022; 13():1089066. PubMed ID: 36578543
[TBL] [Abstract][Full Text] [Related]
5. The emerging role of CDK4/6i in HER2-positive breast cancer.
O'Sullivan CC; Suman VJ; Goetz MP
Ther Adv Med Oncol; 2019; 11():1758835919887665. PubMed ID: 31832106
[TBL] [Abstract][Full Text] [Related]
6. Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies.
Wu X; Yang H; Yu X; Qin JJ
Front Pharmacol; 2022; 13():1012552. PubMed ID: 36210846
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Strategies for Human Epidermal Receptor-2 Positive Metastatic Breast Cancer: A Literature Review.
Sapna F; Athwal PSS; Kumar M; Randhawa S; Kahlon S
Cureus; 2020 Aug; 12(8):e9522. PubMed ID: 32905036
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Xie J; Zou Y; Gao T; Xie L; Tan D; Xie X
Cancer Control; 2022; 29():10732748221099230. PubMed ID: 35499382
[TBL] [Abstract][Full Text] [Related]
9. Treatment Landscape for Patients with HER2-Positive Metastatic Breast Cancer: A Review on Emerging Treatment Options.
Gampenrieder SP; Castagnaviz V; Rinnerthaler G; Greil R
Cancer Manag Res; 2020; 12():10615-10629. PubMed ID: 33149670
[TBL] [Abstract][Full Text] [Related]
10. Targeting HER2 in breast cancer: new drugs and paradigms on the horizon.
Tarantino P; Morganti S; Curigliano G
Explor Target Antitumor Ther; 2021; 2(2):139-155. PubMed ID: 36046143
[TBL] [Abstract][Full Text] [Related]
11. Beyond trastuzumab: new treatment options for HER2-positive breast cancer.
Saini KS; Azim HA; Metzger-Filho O; Loi S; Sotiriou C; de Azambuja E; Piccart M
Breast; 2011 Oct; 20 Suppl 3():S20-7. PubMed ID: 22015288
[TBL] [Abstract][Full Text] [Related]
12. NCAPG confers trastuzumab resistance via activating SRC/STAT3 signaling pathway in HER2-positive breast cancer.
Jiang L; Ren L; Chen H; Pan J; Zhang Z; Kuang X; Chen X; Bao W; Lin C; Zhou Z; Huang D; Yang J; Huang H; Wang L; Hou N; Song L
Cell Death Dis; 2020 Jul; 11(7):547. PubMed ID: 32683421
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant therapeutic approaches of HER2-positive breast cancer with a focus on neratinib maleate.
Kotecki N; Gombos A; Awada A
Expert Rev Anticancer Ther; 2019 Jun; 19(6):447-454. PubMed ID: 31082272
[No Abstract] [Full Text] [Related]
14. New protein kinase inhibitors in breast cancer: afatinib and neratinib.
Zhang X; Munster PN
Expert Opin Pharmacother; 2014 Jun; 15(9):1277-88. PubMed ID: 24787047
[TBL] [Abstract][Full Text] [Related]
15. YES1 activation induces acquired resistance to neratinib in HER2-amplified breast and lung cancers.
Takeda T; Yamamoto H; Suzawa K; Tomida S; Miyauchi S; Araki K; Nakata K; Miura A; Namba K; Shien K; Soh J; Shien T; Kitamura Y; Sendo T; Toyooka S
Cancer Sci; 2020 Mar; 111(3):849-856. PubMed ID: 31856375
[TBL] [Abstract][Full Text] [Related]
16. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
Spector NL; Blackwell KL
J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2
Nagpal A; Redvers RP; Ling X; Ayton S; Fuentes M; Tavancheh E; Diala I; Lalani A; Loi S; David S; Anderson RL; Smith Y; Merino D; Denoyer D; Pouliot N
Breast Cancer Res; 2019 Aug; 21(1):94. PubMed ID: 31409375
[TBL] [Abstract][Full Text] [Related]
18. Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects.
Brandão M; Pondé NF; Poggio F; Kotecki N; Salis M; Lambertini M; de Azambuja E
Expert Rev Anticancer Ther; 2018 Jul; 18(7):629-649. PubMed ID: 29781317
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer.
O'Sullivan CC; Smith KL
Curr Breast Cancer Rep; 2014 Sep; 6(3):169-182. PubMed ID: 25285186
[TBL] [Abstract][Full Text] [Related]
20. Optimal treatment of early stage HER2-positive breast cancer.
Pernas S; Barroso-Sousa R; Tolaney SM
Cancer; 2018 Dec; 124(23):4455-4466. PubMed ID: 30291791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]